secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001193125-25-026659
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma reports Q2 FY2025 net loss of $7.4M, cash at $78.3M; five patients treated with BB-301 in Phase 1b/2a
--------------------------------------------------------------------------------

- Net loss $7.4M ($0.33/sh) vs $6.8M ($2.64/sh) year ago; basic shares rose from 2.6M to 22.1M on warrant exercises.
- Cash and equivalents $78.3M at Dec 31, 2024, up from $50.9M; includes $39.5M from warrant exercises.
- G&A expenses $3.5M (up from $1.8M); R&D flat at $5.1M; total operating expenses $8.6M.
- Fifth subject safely treated with low-dose BB-301 in OPMD study; sixth subject expected in Q2 2025.
- Interim clinical data to be presented in late-breaking oral at MDA conference on March 19, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525026659/0001193125-25-026659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525026659/d877190d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-026659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer